Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 3/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | GNRHR | P30968 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345783 | 0.88 | RAB9A (0.39) | RAB9AMEN1KMT2ANPC1LMNA | |
| SCHEMBL25383393 | 0.79 | NR1H2 (0.42) | PKMRAB9AMEN1KMT2ANPC1 | |
| Trifluoroacetic Acid SCHEMBL345531 | 0.78 | KMT2A (0.34) | RAB9AMEN1KMT2ANPC1MAPT | |
| SCHEMBL8510015 | 0.78 | GABRA5 (0.39) | PKMRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL344922 | 0.77 | ADRB1 (0.38) | PKMRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL9993007 | 0.77 | MEN1 (0.39) | PKMRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL8513707 | 0.76 | RAB9A (0.36) | RAB9AMEN1KMT2ANPC1MAPT | |
| SCHEMBL8513705 | 0.76 | RAB9A (0.36) | RAB9AMEN1KMT2ANPC1MAPT | |
| SCHEMBL8513710 | 0.76 | RAB9A (0.36) | RAB9AMEN1KMT2ANPC1MAPT | |
| SCHEMBL9993018 | 0.76 | NAMPT (0.53) | PKMNAMPTSCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716289-B2 | Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | PKM 2791/4885RAB9A 331/4885MEN1 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.